[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Stihler Electronic Gmbh\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":160},{"warningLetters":4,"total":159},[5,30,49,66,85,106,124,142],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},1651,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-01-23T14:20:00Z\">01\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-08T05:00:00Z\">12\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-airis-electronic-co-ltd-673296-12082023\">Shenzhen Airis Electronic Co. Ltd.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Shenzhen Airis Electronic Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@airistech.com\"> info@airistech.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 8, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.airisvape.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1 and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobaccoproducts\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.airisvape.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: Airis Lux P5000 Disposable Vape, Tropical Fruit; and Airis Titan Disposable Vape 10k Puff, Strawberry Mango.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application requesting marketing authorization for the products listed in this Warning Letter. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2302071, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Bizcn.com, Inc.\u003Cbr>\nabuse@bizcn.com\u003C\u002Fp>\n\n\u003Cp>Aceville PTE LTD-SG\u003Cbr>\nqcloud_net_duty@tencent.com\u003C\u002Fp>\n\n\u003Cp>Discount Vape Pen\u003Cbr>\ncontact@discountvapepen.zendesk.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nShenzhen Airis Electronic Co. Ltd.\n\nChina\n\ninfo@airistech.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDecember 8, 2023\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.airisvape.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1 and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobaccoproducts\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.airisvape.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: Airis Lux P5000 Disposable Vape, Tropical Fruit; and Airis Titan Disposable Vape 10k Puff, Strawberry Mango.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has not received an application requesting marketing authorization for the products listed in this Warning Letter. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2302071, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nBizcn.com, Inc.\n\nabuse@bizcn.com\n\nAceville PTE LTD-SG\n\nqcloud_net_duty@tencent.com\n\nDiscount Vape Pen\n\ncontact@discountvapepen.zendesk.com","Shenzhen Airis Electronic Co. Ltd.","shenzhen-airis-electronic-co-ltd-673296-12082023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-airis-electronic-co-ltd-673296-12082023","2026-10-26T08:09:56.275343+00:00","Warning Letter","Issued","2024-01-23","673296","Tobacco","2026-08-20T00:22:20.67+00:00","VIA Electronic Mail","2023-12-08",{"id":31,"raw":32,"subject":12,"body_html":36,"body_text":37,"firm_name":38,"letter_id":39,"created_at":40,"fei_number":19,"letter_url":41,"updated_at":42,"action_type":22,"case_status":23,"posted_date":43,"marcs_cms_no":44,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":45,"delivery_method":46,"recipient_title":19,"reference_number":47,"action_taken_date":48,"medical_device_id":19,"response_letter_date":19},533,[33,34,35,11,12,13,13,13],"\u003Ctime datetime=\"2025-10-21T04:00:00Z\">10\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-17T04:00:00Z\">10\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felectronicpuffscom-718500-10172025\">electronicpuffs.com\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2502362\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>electronicpuffs.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15 Hayes Ct, Unit 103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Monroe\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10950\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:electronicpuffs@gmail.com\"> electronicpuffs@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:brian@electronicpuffs.com\"> brian@electronicpuffs.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:marketing.electronicpuff@gmail.com\"> marketing.electronicpuff@gmail.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 17, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Felectronicpuffs.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: StarMax Disposables 30K Puffs 5% - Box of 5 – Naked Clear and StarMax Disposables 30K Puffs 5% - Box of 5 – Fresh Tobacco.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2502362, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003C\u002Fp>\u003Cp>Octagon Squared LLC d\u002Fb\u002Fa Electronic Puffs\u003Cbr>Attn: Brian Gutlove\u003Cbr>317 Buckingham Rd\u003Cbr>Cedarhurst, NY 11516\u003C\u002Fp>\u003Cp>GoDaddy.com, LLC\u003Cbr>abuse@godaddy.com\u003C\u002Fp>\u003Cp>SC “Lithuanian Radio and TV Center”\u003Cbr>lir@telecentras.lt\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2502362\n\nProduct:\n\nTobacco\n\nRecipient:\n\nelectronicpuffs.com\n\n15 Hayes Ct, Unit 103\n\nMonroe, NY 10950\n\nUnited States\n\nelectronicpuffs@gmail.com\n\nbrian@electronicpuffs.com\n\nmarketing.electronicpuff@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 17, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Felectronicpuffs.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: StarMax Disposables 30K Puffs 5% - Box of 5 – Naked Clear and StarMax Disposables 30K Puffs 5% - Box of 5 – Fresh Tobacco.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2502362, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA UPS and Electronic Mail\ncc:\nOctagon Squared LLC d\u002Fb\u002Fa Electronic Puffs\nAttn: Brian Gutlove\n317 Buckingham Rd\nCedarhurst, NY 11516\nGoDaddy.com, LLC\nabuse@godaddy.com\nSC “Lithuanian Radio and TV Center”\nlir@telecentras.lt","electronicpuffs.com","electronicpuffscom-718500-10172025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felectronicpuffscom-718500-10172025","2026-10-26T08:08:34.054301+00:00","2025-10-21","718500","2026-08-19T16:13:20.915+00:00","VIA UPS and Electronic Mail","RW2502362","2025-10-17",{"id":50,"raw":51,"subject":12,"body_html":55,"body_text":56,"firm_name":57,"letter_id":58,"created_at":40,"fei_number":19,"letter_url":59,"updated_at":60,"action_type":22,"case_status":23,"posted_date":61,"marcs_cms_no":62,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":63,"delivery_method":46,"recipient_title":19,"reference_number":64,"action_taken_date":65,"medical_device_id":19,"response_letter_date":19},948,[52,53,54,11,12,13,13,13],"\u003Ctime datetime=\"2025-04-28T04:00:00Z\">04\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-24T04:00:00Z\">04\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsparkys-electronic-cigarettes-701655-04242025\">Sparky’s Electronic Cigarettes\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501131\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Sparky’s Electronic Cigarettes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2060 West River Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tucson\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85704\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 24, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Sparky’s Electronic Cigarettes manufactures, sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Yankee.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501131, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501131\n\nProduct:\n\nTobacco\n\nRecipient:\n\nSparky’s Electronic Cigarettes\n\n2060 West River Road\n\nTucson, AZ 85704\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nApril 24, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Sparky’s Electronic Cigarettes manufactures, sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Yankee.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501131, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Sparky’s Electronic Cigarettes","sparkys-electronic-cigarettes-701655-04242025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsparkys-electronic-cigarettes-701655-04242025","2026-10-26T08:10:02.410416+00:00","2025-04-28","701655","2026-08-19T16:51:52.496+00:00","ER2501131","2025-04-24",{"id":67,"raw":68,"subject":12,"body_html":72,"body_text":73,"firm_name":74,"letter_id":75,"created_at":76,"fei_number":19,"letter_url":77,"updated_at":78,"action_type":22,"case_status":23,"posted_date":79,"marcs_cms_no":80,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":81,"body_fetched_at":82,"delivery_method":28,"recipient_title":19,"reference_number":83,"action_taken_date":84,"medical_device_id":19,"response_letter_date":19},2108,[69,70,71,11,12,13,13,13],"\u003Ctime datetime=\"2023-05-09T13:20:00Z\">05\u002F09\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-02T04:00:00Z\">05\u002F02\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjoyetech-shenzhen-electronics-co-ltd-658046-05022023\">Joyetech Shenzhen Electronics Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2301917\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Xuefeng Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Joyetech Shenzhen Electronics Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@joyetech.com\"> info@joyetech.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:service@joyetech.com\"> service@joyetech.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Xuefeng Zhang:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the websites https:\u002F\u002Fwww.joyetech.com and https:\u002F\u002Fstore.joyetech.com, and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the websites https:\u002F\u002Fwww.joyetech.com and https:\u002F\u002Fstore.joyetech.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: VAAL EP4500 Dispsable [\u003Cem>sic\u003C\u002Fem>] Kit 4500 Puffs, Cherry Coke; VAAL GLAZ 6500 Disposable Kit 6500 Puffs 13ml, Cotton Candy; and VAAL Tenk Disposable Kit 10000 Puffs 20ml Rechargeable, Lush Ice.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301917, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Joyetech Shenzhen Electronics Co., Ltd.\u003Cbr>\nmarketing@joyetech.com\u003Cbr>\ncustomer@joyetech.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Cloudflare, Inc.\u003Cbr>\nabuse@cloudflare.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\nRW2301917\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nXuefeng Zhang\n\nJoyetech Shenzhen Electronics Co., Ltd.\n\nUnited States\n\ninfo@joyetech.com\n\nservice@joyetech.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDear Xuefeng Zhang:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the websites https:\u002F\u002Fwww.joyetech.com and https:\u002F\u002Fstore.joyetech.com, and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the websites https:\u002F\u002Fwww.joyetech.com and https:\u002F\u002Fstore.joyetech.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: VAAL EP4500 Dispsable [sic] Kit 4500 Puffs, Cherry Coke; VAAL GLAZ 6500 Disposable Kit 6500 Puffs 13ml, Cotton Candy; and VAAL Tenk Disposable Kit 10000 Puffs 20ml Rechargeable, Lush Ice.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301917, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nJoyetech Shenzhen Electronics Co., Ltd.\n\nmarketing@joyetech.com\n\ncustomer@joyetech.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nCloudflare, Inc.\n\nabuse@cloudflare.com","Joyetech Shenzhen Electronics Co., Ltd.","joyetech-shenzhen-electronics-co-ltd-658046-05022023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjoyetech-shenzhen-electronics-co-ltd-658046-05022023","2026-10-26T08:09:05.568967+00:00","2023-05-09","658046","Xuefeng Zhang","2026-08-20T01:07:33.848+00:00","RW2301917","2023-05-02",{"id":86,"raw":87,"subject":92,"body_html":93,"body_text":94,"firm_name":95,"letter_id":96,"created_at":97,"fei_number":19,"letter_url":98,"updated_at":99,"action_type":22,"case_status":23,"posted_date":100,"marcs_cms_no":101,"product_type":102,"closeout_date":19,"issuing_office":91,"recipient_name":103,"body_fetched_at":104,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":105,"medical_device_id":19,"response_letter_date":19},454,[88,89,90,91,92,13,13,13],"\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-28T04:00:00Z\">10\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhong-qiangxing-shenzhen-electronics-limited-718112-10282025\">Hong Qiangxing Shenzhen Electronics Limited\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Zhu Shi Hong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and Management Representative\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hong Qiangxing Shenzhen Electronics Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2F, Yongcheng Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Xicheng Industrial Area, Xixiang Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bao'an Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>518126\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:1049936065@qq.com\"> 1049936065@qq.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 28, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #: 718112\u003C\u002Fp>\u003Cp>Dear Zhu Shi Hong:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Shenzhen, Guangdong, China, on August 4, 2025, through August 7, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wrist blood pressure monitors, Belifu TENS001 (Model SM9126), and various transcutaneous electric nerve stimulators (TENS) and powered muscle stimulator (PMS) devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Zhu Shi Hong, Vice President and Management Representative, dated August 21, 2025, September 26, 2025, and October 8, 2025, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to control the design of the devices to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically:\u003C\u002Fp>\u003Cp>a) Failure to adequately validate device software, as required by 21 CFR 820.30(g). Your firm failed to adequately verify and validate the operating software for the TENS and PMS Model SM9109A.&nbsp;\u003C\u002Fp>\u003Cp>This is a repeat violation from the July 2016 inspection.&nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025, responses and conclude that they are not adequate. In these responses, your firm provided a corrective and preventive action (CAPA) report. The report identified the root causes as 1) lack of specific inspection and confirmation of the software during the burning process, and 2) lack of establishment of control procedures for the software burning process.\u003C\u002Fp>\u003Cp>Your firm identified CAPAs to be taken as 1) establish the \"Software burn-in Procedure,\" requiring the burn-in operators to confirm the burn-in version and conduct the initial burn-in inspection, carry out the burn-in process only after the initial inspection is passed, and conduct inspections and record the burn-in status every hour during the burn-in process; 2) record the software burn-in information, initial inspection results, and the burn-in process in a “Software burn-in Record;” and 3) conduct training for the engineering department on the new procedure. In the response dated October 8, 2025, your firm provided a copy of the newly established “Software Burning Procedure.” However, the response does not address retrospective review to ensure that software on previously manufactured devices is validated.\u003C\u002Fp>\u003Cp>b) Failure to adequately establish procedures for design change, as required by 21 CFR 820.30(i). Your change control procedures do not adequately ensure that the description of the change, the reason for the change, and the impact of the change is adequately evaluated and that the evaluation and results are documented. For example, three out of three change records reviewed involving changes to the TENS and PMS devices [Model SM9109A (RL-109A-6A1) and Model TENS7000 (RL-069)] and the Model SM 9019 (RL-0198-2C1) Remote Controller documented in ECN20240626001, ECN20231026001, and ECN20250425001 lacked adequate documentation of the change description, the reason for the change, and the evaluation of the impact of the change.&nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025, responses and conclude that they are not adequate. In these responses, your firm provided a CAPA report. The report identified the root causes as 1) a lack of planning for changes, resulting in insufficient information during the change process and absence of verification requirements, 2) a lack of planning for the changes due to the failure to implement an engineering change request (ECR) review or to effectively control the change process and verification, and 3) the absence of specific requirements for the execution and approval of ECR, so that verification was missing during the change process.\u003C\u002Fp>\u003Cp>Your firm identified the following CAPAs in response: 1) update the COP-414-01 change control procedure and add the requirement that an ECR review must be conducted before the change, and 2) include in the ECR content the source of the change requirement, a comparison of devices before and after the change, an evaluation of the safety and effectiveness of the change impact, an assessment of foreseeable risks arising from the change, and a change verification plan, including a sampling plan, inspection basis record requirements, and sample requirements. Additionally, the report states that training will be conducted on the new \"Change Control Procedure\" and requirements of the ECR. The response dated October 8, 2025, includes evidence of the above described CAPAs, including an updated “Change Control Procedure.” However, your response does not address retrospective review to ensure that all previous changes have been adequately documented and evaluated.\u003C\u002Fp>\u003Cp>c) Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Your rationale for the sample size used in design validation for the low frequency Electronic Pulse Therapy Device Model SM9109A (RL-6A1) is not documented. Additionally, the device samples used in design validation were manufactured by the engineering department and were not produced under defined operating conditions as initial production units, lots, or batches or their equivalents. This is a repeat violation from the July 2016 inspection.\u003C\u002Fp>\u003Cp>d) Failure to establish and maintain procedures for verifying the device design, as required by 21 CFR 820.30(f). Your rationale for the sample size used in design verification for the low frequency Electronic Pulse Therapy Device Model SM9109A (RL-6A1) is not documented. This is a repeat violation from the July 2016 inspection.\u003C\u002Fp>\u003Cp>e) Failure to ensure that the design history file demonstrates that the design was developed following the requirements of 21 CFR 820, as required by 21 CFR 820.30(j). Your design verification and design validation for the low frequency Electronic Pulse Therapy Device Model SM9109A (RL-6A1) are inadequate in that the raw data in support of the design verification and validation are not documented, and that there are not documented manufacturing records for the samples used in verification and validation. This is a repeat violation from the July 2016 inspection.&nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025, responses and conclude that they are not adequate. In these responses, your firm provided a CAPA report. The report identifies the root causes as 1) a lack of planning for changes, resulting in insufficient information during the change process and absence of verification requirements, 2) a lack of planning for the changes due to the failure to implement an ECR review and the change process and verification were not effectively controlled, and 3) the absence of specific requirements for the execution and approval of an ECR so that verification was missing during the change process.\u003C\u002Fp>\u003Cp>Your firm identified the following CAPAs in response: 1) update the COP-414-01 change control procedure and add the requirement that an ECR review must be conducted before the change, and 2) include in the ECR content the source of the change requirement, comparison of the device before and after the change, evaluation of the safety and effectiveness of the change impact, assessment of foreseeable risks arising from the change, and the change verification plan, including sampling plan, inspection basis record requirements, and sample requirements. Additionally, the report states that training will be conducted on the new \"Change Control Procedure\" and requirements of the ECR. The response dated October 8, 2025, includes evidence of the above described CAPAs, including an updated “Change Control Procedure.” However, this response does not address systemically inadequate design verification and validation reports, including a lack of documentation of raw data in support of the design verification and validation and a lack of documented justification of sample size. Additionally, it does not ensure that device samples used in design verification and validation are manufactured under defined operating conditions as initial production units, lots, or batches, or their equivalents, or that documented manufacturing records confirm the samples are used in verification and validation under normal manufacturing conditions in cases when there is not a design change. Similarly, your response does not address retrospective review to ensure design verification and validation of any devices already made and\u002For in storage.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, COP-830-01, “Control of Nonconforming Product,” does not ensure that the disposition of nonconforming product is documented or include a justification for use of nonconforming product. For example, a justification for use of nonconforming products is not documented in the Nonconforming Review and Disposal Form No. 20240103001. The dispositions of nonconforming products in Nonconforming Review and Disposal Forms No. 2025010803 and No. 2024082001 were also not documented.\u003C\u002Fp>\u003Cp>Further, this is a repeat violation from the July 2016 inspection.&nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025, responses and conclude that they are not adequate. In these responses, your firm provided a CAPA report. Your firm identified root causes including that 1) the material on nonconformance handling forms identified in the inspection all underwent special acceptance and were approved but the special acceptance details were not recorded in the records; 2) there is no dedicated special acceptance review form established in the process of handling nonconforming products, so the special acceptance information is not reflected; and 3) there are no detailed procedures on the special acceptance process in COP-830-01, “Control of Nonconforming Product,” resulting in incomplete special acceptance information.\u003C\u002Fp>\u003Cp>Your firm identified CAPAs as: 1) establish the \"special acceptance request\" requiring that the special acceptance process must describe and approve the information and quantity, and specify any expected risks of the special acceptance materials; 2) reapply for special acceptance for the nonconforming product handling forms identified during the inspection to ensure the completeness of the special acceptance information; and 3) revise COP-830-01, “Control of Nonconforming Product,” to add the \"special acceptance request\" requirement and stipulate that direct use, selective use, and production processing all fall under the \"special acceptance\" process. The \"special acceptance request\" form should be filled out by the department with special acceptance requirements, including the description of the nonconforming product, the expected risks generated by special acceptance, the special acceptance suggestions, and the quantity of special acceptance. After being approved by relevant departments and the management representative, special acceptance can be carried out.\u003C\u002Fp>\u003Cp>In the response dated October 8, 2025, your firm provided evidence of the above described CAPA, including an updated COP-830-01 procedure with a section on a \"Special Procurement Application,\" specifying conditions in which nonconforming materials can be used for specific purposes after appropriate approval. Your firm also provided copies of a \"Special Acceptance Request\" form, filled out per the \"Special Procurement Application\" process, for the specific cases referenced in this observation. However, the responses do not address retrospective review to ensure that any other previous nonconformance handling forms not reviewed during the inspection are also appropriately reviewed and documented according to the updated procedure.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish procedures for corrective and preventive action as required by 21 CFR 820.100(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, a) the corrective and preventive action procedures do not ensure that sources of quality data are adequately analyzed to identify existing and potential causes of nonconforming product or other quality problems; b) CAPA 2025022501 was not adequately investigated to identify corrective actions and the effectiveness of the actions taken was not verified; and c) the effectiveness of the actions taken in CAPA 2025060401 were not verified.&nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025 responses and conclude that they are not adequate. In these responses, your firm provided a CAPA report. Your firm identified the root causes for inadequacies in these two CAPA forms as 1) a delay in receiving complaint information from American distributors and confirmation of the problem which required no adjustment to the complaint from the distributor, and 2) a lack of stipulation in COP-821-01, “Customer Complaint Feedback Control Procedure,” for the handling of defective products after they are returned, such that the quality department did not update the CAPA, and 3) a lack of regulations in COP-630-01, “Facility and Equipment Management Procedure,” for the handling of facilities and equipment after adjustment, such that the engineering department did not conduct any verification after implementing a change resulting from a complaint.\u003C\u002Fp>\u003Cp>Your firm’s proposed CAPA includes 1) re-examining the root cause analysis of the first CAPA form to confirm the fundamental reason for the problem that led to the returned product, 2) re-validating the corrective action and providing the investigation and verification results to the customer, and 3) revising COP-821-01, “Customer Feedback Control Procedure,” to add the requirement that \"After the customer returns the defective products due to complaints, re-inspection shall be conducted to confirm whether the defects are consistent with the descriptions provided by the distributor or the user.\" Additionally, the actions include 1) carrying out small-scale trial production of the adjusted line speed of the packaging line to verify the effectiveness of the previous corrective action, and 2) updating COP-630-01, “Facility and Equipment Management Procedure,” and adding the requirement that \"Facility and equipment should be adjusted according to production requirements. After the adjustment, it needs to undergo small-scale trial production verification to confirm the adjustment [is] effect[ive] before use.\" The response dated October 8, 2025, provided evidence of the above described CAPA, including copies of the revised CAPA forms and an updated COP-630-01 procedure. However, the responses do not address how your firm will validate the effectiveness of future CAPAs or include retrospective review to ensure effectiveness of other previous CAPA reports.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, the complaint handling procedures do not ensure that complaints are processed in a uniform and timely manner or that they are adequately investigated and evaluated for submission of a medical device report (MDR). For example, 4 out of 4 complaints reviewed were not adequately investigated and lacked documented MDR evaluation. One of the complaint records reviewed, Customer Complaint Form No. 23081101, included two separate reported malfunctions of two different TENS and PMS devices received on different dates from the same customer. Your firm failed to create separate reports to adequately process, investigate, and evaluate each complaint.&nbsp;\u003C\u002Fp>\u003Cp>Your firm’s responses, dated August 21, 2025, September 26, 2025, and October 8, 2025, appear to be adequate. In these responses, your firm provided a CAPA report. Your firm identified root causes, including that the review requirements for the submission of an FDA MDR were not reflected on the customer complaint handling form, so the marketing department did not assess the MDR requirements. In one complaint (number 23081101), the customer mentioned both the ZX-518BM and the 587B device models, but the inventory checks were recorded on a single form. As there were no specific requirements in the complaint feedback control procedure for situations where a single complaint involved multiple device models or products, the investigation did not distinguish between them. Your firm identified CAPAs, including 1) revising the customer complaint handling form QR-821-05\u002F00 to add the FDA MDR assessment requirements, 2) re-evaluating the customer complaints handling from 2025, 2024, and 2023 to determine whether an FDA MDR is necessary, 3) revising the customer feedback control procedure COP-821-01 to add information about MDR procedures, and 4) revising the customer feedback control procedure COP-821-01 to specify that if a complaint involves multiple products or different models, a separate investigation needs to be conducted for each product or model. In the response dated October 8, 2025, your firm provided evidence of the CAPA investigation, including an updated version of the COP-821-01 procedure.\u003C\u002Fp>\u003Cp>5. Failure to adequately establish procedures for identifying product during all stages of receipt, production, distribution, and installation, as required by 21 CFR 820.60.&nbsp;\u003C\u002Fp>\u003Cp>Specifically, during the walk through inspection, the investigator observed an unidentified box of what appeared to be in-process, partly assembled TENS and PMS units on a work bench and a case of unidentified in-process, semi-assembled TENS and PMS units stored on a pallet on the floor near a soldering workstation in the production room. In various areas, such as in the receiving\u002Fshipping and production rooms, there were unidentified, opened and half-opened boxes and a variety of materials and production and test equipment that your firm stated were obsolete and no longer in use.&nbsp;\u003C\u002Fp>\u003Cp>Your firm’s responses, dated August 21, 2025, September 26, 2025, and October 8, 2025, appear to be adequate. In these responses, your firm provided a CAPA report. Your firm identified root causes including: 1) a failure of the production department to properly organize materials in time due to the large volume of production tasks and the abundance of materials, 2) a lack of production environment control measures that resulted in the production materials not being assigned to specific storage areas, and 3) a lack of production environment control procedures, leading to a lack of production environment inspections and the disorderly placement of materials.\u003C\u002Fp>\u003Cp>Your firm identified CAPAs including 1) establish production environment control procedures to set requirements for the placement of materials in the production area and the cleanliness of the environment, and 2) establish a checklist for the production environment and conduct daily inspections of the production environment. In the response dated October 8, 2025, your firm provided evidence of the CAPA implementation, including a copy of the newly established \"Production Environment Management Regulations\" procedure and a production environment inspection record form demonstrating inspection of the production environment beginning in mid-August 2025.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Federal Food, Drug, and Cosmetic (FD&amp;C) Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm's response should be sent via email to Tushar Bansal, Ph.D., at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS case # 718112 when replying. If you have any questions about the contents of this letter, please contact: Tushar Bansal, Ph.D., at Tushar.Bansal@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>David McMullen, M.D.\u003Cbr>Director\u003Cbr>OHT5: Office of Neurological\u003Cbr>&nbsp; &nbsp; and Physical Medicine Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Mark Gordon\u003Cbr>1800 Byberry Road Suite 905\u003Cbr>Huntingdon Valley, PA 19006\u003Cbr>920-601-9045\u003Cbr>\u003Cstrong>(b)(6)\u003C\u002Fstrong>@outlook.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nZhu Shi Hong\n\nRecipient Title\n\nVice President and Management Representative\n\nHong Qiangxing Shenzhen Electronics Limited\n\n2F, Yongcheng Boulevard\n\nXicheng Industrial Area, Xixiang Road\n\nBao'an Qu\n\nShenzhen Shi\n\nGuangdong Sheng, 518126\n\nChina\n\n1049936065@qq.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nOctober 28, 2025\nWARNING LETTER\nCMS #: 718112\nDear Zhu Shi Hong:\nDuring an inspection of your firm located in Shenzhen, Guangdong, China, on August 4, 2025, through August 7, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wrist blood pressure monitors, Belifu TENS001 (Model SM9126), and various transcutaneous electric nerve stimulators (TENS) and powered muscle stimulator (PMS) devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Zhu Shi Hong, Vice President and Management Representative, dated August 21, 2025, September 26, 2025, and October 8, 2025, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to control the design of the devices to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically:\na) Failure to adequately validate device software, as required by 21 CFR 820.30(g). Your firm failed to adequately verify and validate the operating software for the TENS and PMS Model SM9109A.\nThis is a repeat violation from the July 2016 inspection.\nWe reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025, responses and conclude that they are not adequate. In these responses, your firm provided a corrective and preventive action (CAPA) report. The report identified the root causes as 1) lack of specific inspection and confirmation of the software during the burning process, and 2) lack of establishment of control procedures for the software burning process.\nYour firm identified CAPAs to be taken as 1) establish the \"Software burn-in Procedure,\" requiring the burn-in operators to confirm the burn-in version and conduct the initial burn-in inspection, carry out the burn-in process only after the initial inspection is passed, and conduct inspections and record the burn-in status every hour during the burn-in process; 2) record the software burn-in information, initial inspection results, and the burn-in process in a “Software burn-in Record;” and 3) conduct training for the engineering department on the new procedure. In the response dated October 8, 2025, your firm provided a copy of the newly established “Software Burning Procedure.” However, the response does not address retrospective review to ensure that software on previously manufactured devices is validated.\nb) Failure to adequately establish procedures for design change, as required by 21 CFR 820.30(i). Your change control procedures do not adequately ensure that the description of the change, the reason for the change, and the impact of the change is adequately evaluated and that the evaluation and results are documented. For example, three out of three change records reviewed involving changes to the TENS and PMS devices [Model SM9109A (RL-109A-6A1) and Model TENS7000 (RL-069)] and the Model SM 9019 (RL-0198-2C1) Remote Controller documented in ECN20240626001, ECN20231026001, and ECN20250425001 lacked adequate documentation of the change description, the reason for the change, and the evaluation of the impact of the change.\nWe reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025, responses and conclude that they are not adequate. In these responses, your firm provided a CAPA report. The report identified the root causes as 1) a lack of planning for changes, resulting in insufficient information during the change process and absence of verification requirements, 2) a lack of planning for the changes due to the failure to implement an engineering change request (ECR) review or to effectively control the change process and verification, and 3) the absence of specific requirements for the execution and approval of ECR, so that verification was missing during the change process.\nYour firm identified the following CAPAs in response: 1) update the COP-414-01 change control procedure and add the requirement that an ECR review must be conducted before the change, and 2) include in the ECR content the source of the change requirement, a comparison of devices before and after the change, an evaluation of the safety and effectiveness of the change impact, an assessment of foreseeable risks arising from the change, and a change verification plan, including a sampling plan, inspection basis record requirements, and sample requirements. Additionally, the report states that training will be conducted on the new \"Change Control Procedure\" and requirements of the ECR. The response dated October 8, 2025, includes evidence of the above described CAPAs, including an updated “Change Control Procedure.” However, your response does not address retrospective review to ensure that all previous changes have been adequately documented and evaluated.\nc) Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Your rationale for the sample size used in design validation for the low frequency Electronic Pulse Therapy Device Model SM9109A (RL-6A1) is not documented. Additionally, the device samples used in design validation were manufactured by the engineering department and were not produced under defined operating conditions as initial production units, lots, or batches or their equivalents. This is a repeat violation from the July 2016 inspection.\nd) Failure to establish and maintain procedures for verifying the device design, as required by 21 CFR 820.30(f). Your rationale for the sample size used in design verification for the low frequency Electronic Pulse Therapy Device Model SM9109A (RL-6A1) is not documented. This is a repeat violation from the July 2016 inspection.\ne) Failure to ensure that the design history file demonstrates that the design was developed following the requirements of 21 CFR 820, as required by 21 CFR 820.30(j). Your design verification and design validation for the low frequency Electronic Pulse Therapy Device Model SM9109A (RL-6A1) are inadequate in that the raw data in support of the design verification and validation are not documented, and that there are not documented manufacturing records for the samples used in verification and validation. This is a repeat violation from the July 2016 inspection.\nWe reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025, responses and conclude that they are not adequate. In these responses, your firm provided a CAPA report. The report identifies the root causes as 1) a lack of planning for changes, resulting in insufficient information during the change process and absence of verification requirements, 2) a lack of planning for the changes due to the failure to implement an ECR review and the change process and verification were not effectively controlled, and 3) the absence of specific requirements for the execution and approval of an ECR so that verification was missing during the change process.\nYour firm identified the following CAPAs in response: 1) update the COP-414-01 change control procedure and add the requirement that an ECR review must be conducted before the change, and 2) include in the ECR content the source of the change requirement, comparison of the device before and after the change, evaluation of the safety and effectiveness of the change impact, assessment of foreseeable risks arising from the change, and the change verification plan, including sampling plan, inspection basis record requirements, and sample requirements. Additionally, the report states that training will be conducted on the new \"Change Control Procedure\" and requirements of the ECR. The response dated October 8, 2025, includes evidence of the above described CAPAs, including an updated “Change Control Procedure.” However, this response does not address systemically inadequate design verification and validation reports, including a lack of documentation of raw data in support of the design verification and validation and a lack of documented justification of sample size. Additionally, it does not ensure that device samples used in design verification and validation are manufactured under defined operating conditions as initial production units, lots, or batches, or their equivalents, or that documented manufacturing records confirm the samples are used in verification and validation under normal manufacturing conditions in cases when there is not a design change. Similarly, your response does not address retrospective review to ensure design verification and validation of any devices already made and\u002For in storage.\n2. Failure to adequately establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nSpecifically, COP-830-01, “Control of Nonconforming Product,” does not ensure that the disposition of nonconforming product is documented or include a justification for use of nonconforming product. For example, a justification for use of nonconforming products is not documented in the Nonconforming Review and Disposal Form No. 20240103001. The dispositions of nonconforming products in Nonconforming Review and Disposal Forms No. 2025010803 and No. 2024082001 were also not documented.\nFurther, this is a repeat violation from the July 2016 inspection.\nWe reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025, responses and conclude that they are not adequate. In these responses, your firm provided a CAPA report. Your firm identified root causes including that 1) the material on nonconformance handling forms identified in the inspection all underwent special acceptance and were approved but the special acceptance details were not recorded in the records; 2) there is no dedicated special acceptance review form established in the process of handling nonconforming products, so the special acceptance information is not reflected; and 3) there are no detailed procedures on the special acceptance process in COP-830-01, “Control of Nonconforming Product,” resulting in incomplete special acceptance information.\nYour firm identified CAPAs as: 1) establish the \"special acceptance request\" requiring that the special acceptance process must describe and approve the information and quantity, and specify any expected risks of the special acceptance materials; 2) reapply for special acceptance for the nonconforming product handling forms identified during the inspection to ensure the completeness of the special acceptance information; and 3) revise COP-830-01, “Control of Nonconforming Product,” to add the \"special acceptance request\" requirement and stipulate that direct use, selective use, and production processing all fall under the \"special acceptance\" process. The \"special acceptance request\" form should be filled out by the department with special acceptance requirements, including the description of the nonconforming product, the expected risks generated by special acceptance, the special acceptance suggestions, and the quantity of special acceptance. After being approved by relevant departments and the management representative, special acceptance can be carried out.\nIn the response dated October 8, 2025, your firm provided evidence of the above described CAPA, including an updated COP-830-01 procedure with a section on a \"Special Procurement Application,\" specifying conditions in which nonconforming materials can be used for specific purposes after appropriate approval. Your firm also provided copies of a \"Special Acceptance Request\" form, filled out per the \"Special Procurement Application\" process, for the specific cases referenced in this observation. However, the responses do not address retrospective review to ensure that any other previous nonconformance handling forms not reviewed during the inspection are also appropriately reviewed and documented according to the updated procedure.\n3. Failure to adequately establish procedures for corrective and preventive action as required by 21 CFR 820.100(a).\nSpecifically, a) the corrective and preventive action procedures do not ensure that sources of quality data are adequately analyzed to identify existing and potential causes of nonconforming product or other quality problems; b) CAPA 2025022501 was not adequately investigated to identify corrective actions and the effectiveness of the actions taken was not verified; and c) the effectiveness of the actions taken in CAPA 2025060401 were not verified.\nWe reviewed your firm's August 21, 2025, September 26, 2025, and October 8, 2025 responses and conclude that they are not adequate. In these responses, your firm provided a CAPA report. Your firm identified the root causes for inadequacies in these two CAPA forms as 1) a delay in receiving complaint information from American distributors and confirmation of the problem which required no adjustment to the complaint from the distributor, and 2) a lack of stipulation in COP-821-01, “Customer Complaint Feedback Control Procedure,” for the handling of defective products after they are returned, such that the quality department did not update the CAPA, and 3) a lack of regulations in COP-630-01, “Facility and Equipment Management Procedure,” for the handling of facilities and equipment after adjustment, such that the engineering department did not conduct any verification after implementing a change resulting from a complaint.\nYour firm’s proposed CAPA includes 1) re-examining the root cause analysis of the first CAPA form to confirm the fundamental reason for the problem that led to the returned product, 2) re-validating the corrective action and providing the investigation and verification results to the customer, and 3) revising COP-821-01, “Customer Feedback Control Procedure,” to add the requirement that \"After the customer returns the defective products due to complaints, re-inspection shall be conducted to confirm whether the defects are consistent with the descriptions provided by the distributor or the user.\" Additionally, the actions include 1) carrying out small-scale trial production of the adjusted line speed of the packaging line to verify the effectiveness of the previous corrective action, and 2) updating COP-630-01, “Facility and Equipment Management Procedure,” and adding the requirement that \"Facility and equipment should be adjusted according to production requirements. After the adjustment, it needs to undergo small-scale trial production verification to confirm the adjustment [is] effect[ive] before use.\" The response dated October 8, 2025, provided evidence of the above described CAPA, including copies of the revised CAPA forms and an updated COP-630-01 procedure. However, the responses do not address how your firm will validate the effectiveness of future CAPAs or include retrospective review to ensure effectiveness of other previous CAPA reports.\n4. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, the complaint handling procedures do not ensure that complaints are processed in a uniform and timely manner or that they are adequately investigated and evaluated for submission of a medical device report (MDR). For example, 4 out of 4 complaints reviewed were not adequately investigated and lacked documented MDR evaluation. One of the complaint records reviewed, Customer Complaint Form No. 23081101, included two separate reported malfunctions of two different TENS and PMS devices received on different dates from the same customer. Your firm failed to create separate reports to adequately process, investigate, and evaluate each complaint.\nYour firm’s responses, dated August 21, 2025, September 26, 2025, and October 8, 2025, appear to be adequate. In these responses, your firm provided a CAPA report. Your firm identified root causes, including that the review requirements for the submission of an FDA MDR were not reflected on the customer complaint handling form, so the marketing department did not assess the MDR requirements. In one complaint (number 23081101), the customer mentioned both the ZX-518BM and the 587B device models, but the inventory checks were recorded on a single form. As there were no specific requirements in the complaint feedback control procedure for situations where a single complaint involved multiple device models or products, the investigation did not distinguish between them. Your firm identified CAPAs, including 1) revising the customer complaint handling form QR-821-05\u002F00 to add the FDA MDR assessment requirements, 2) re-evaluating the customer complaints handling from 2025, 2024, and 2023 to determine whether an FDA MDR is necessary, 3) revising the customer feedback control procedure COP-821-01 to add information about MDR procedures, and 4) revising the customer feedback control procedure COP-821-01 to specify that if a complaint involves multiple products or different models, a separate investigation needs to be conducted for each product or model. In the response dated October 8, 2025, your firm provided evidence of the CAPA investigation, including an updated version of the COP-821-01 procedure.\n5. Failure to adequately establish procedures for identifying product during all stages of receipt, production, distribution, and installation, as required by 21 CFR 820.60.\nSpecifically, during the walk through inspection, the investigator observed an unidentified box of what appeared to be in-process, partly assembled TENS and PMS units on a work bench and a case of unidentified in-process, semi-assembled TENS and PMS units stored on a pallet on the floor near a soldering workstation in the production room. In various areas, such as in the receiving\u002Fshipping and production rooms, there were unidentified, opened and half-opened boxes and a variety of materials and production and test equipment that your firm stated were obsolete and no longer in use.\nYour firm’s responses, dated August 21, 2025, September 26, 2025, and October 8, 2025, appear to be adequate. In these responses, your firm provided a CAPA report. Your firm identified root causes including: 1) a failure of the production department to properly organize materials in time due to the large volume of production tasks and the abundance of materials, 2) a lack of production environment control measures that resulted in the production materials not being assigned to specific storage areas, and 3) a lack of production environment control procedures, leading to a lack of production environment inspections and the disorderly placement of materials.\nYour firm identified CAPAs including 1) establish production environment control procedures to set requirements for the placement of materials in the production area and the cleanliness of the environment, and 2) establish a checklist for the production environment and conduct daily inspections of the production environment. In the response dated October 8, 2025, your firm provided evidence of the CAPA implementation, including a copy of the newly established \"Production Environment Management Regulations\" procedure and a production environment inspection record form demonstrating inspection of the production environment beginning in mid-August 2025.\nOther federal agencies may take your compliance with the Federal Food, Drug, and Cosmetic (FD&C) Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm's response should be sent via email to Tushar Bansal, Ph.D., at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS case # 718112 when replying. If you have any questions about the contents of this letter, please contact: Tushar Bansal, Ph.D., at Tushar.Bansal@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nDavid McMullen, M.D.\nDirector\nOHT5: Office of Neurological\nand Physical Medicine Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nMark Gordon\n1800 Byberry Road Suite 905\nHuntingdon Valley, PA 19006\n920-601-9045\n(b)(6)@outlook.com","Hong Qiangxing Shenzhen Electronics Limited","hong-qiangxing-shenzhen-electronics-limited-718112-10282025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhong-qiangxing-shenzhen-electronics-limited-718112-10282025","2026-10-26T08:08:55.69131+00:00","2025-11-25","718112","Medical Devices","Zhu Shi Hong","2026-08-19T13:26:22.804+00:00","2025-10-28",{"id":107,"raw":108,"subject":12,"body_html":112,"body_text":113,"firm_name":114,"letter_id":115,"created_at":116,"fei_number":19,"letter_url":117,"updated_at":118,"action_type":22,"case_status":23,"posted_date":119,"marcs_cms_no":120,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":121,"body_fetched_at":122,"delivery_method":46,"recipient_title":19,"reference_number":19,"action_taken_date":123,"medical_device_id":19,"response_letter_date":19},3348,[109,110,111,11,12,13,13,13],"\u003Ctime datetime=\"2021-05-18T13:20:00Z\">05\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-07T04:00:00Z\">05\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcentral-iowa-electronic-cigarettes-inc-614670-05072021\">Central Iowa Electronic Cigarettes Inc\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Corey Halfhill\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Central Iowa Electronic Cigarettes Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11338 Aurora Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Urbandale\u003C\u002Fspan>, \u003Cspan>IA\u003C\u002Fspan> \u003Cspan>50322\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@centraliowaecigs.com\"> info@centraliowaecigs.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:centraliowaecigs@gmail.com\"> centraliowaecigs@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 7, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Corey Halfhill:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fiowaecigs.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fiowaecigs.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: CIV Unicorn Tears, CIV Red Hot Cinnamon, and CIV Tropical Explosion.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 3,400 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101590, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Central Iowa Vapors\u003Cbr>\n3921 E. 14th Street\u003Cbr>\nDes Moines, IA 50313\u003C\u002Fp>\n\n\u003Cp>PrivacyGuardian.org\u003Cbr>\npw-13fca30f88326c8d9c67afe178e0b7b7@privacyguardian.org\u003C\u002Fp>\n\n\u003Cp>NameSilo, LLC\u003Cbr>\nabuse@namesilo.com\u003C\u002Fp>\n\n\u003Cp>Cloudflare, Inc.\u003Cbr>\nabuse@cloudflare.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nCorey Halfhill\n\nCentral Iowa Electronic Cigarettes Inc\n\n11338 Aurora Avenue\n\nUrbandale, IA 50322\n\nUnited States\n\ninfo@centraliowaecigs.com\n\ncentraliowaecigs@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 7, 2021\n\nWARNING LETTER\n\nDear Corey Halfhill:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fiowaecigs.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fiowaecigs.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: CIV Unicorn Tears, CIV Red Hot Cinnamon, and CIV Tropical Explosion.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 3,400 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101590, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nCentral Iowa Vapors\n\n3921 E. 14th Street\n\nDes Moines, IA 50313\n\nPrivacyGuardian.org\n\npw-13fca30f88326c8d9c67afe178e0b7b7@privacyguardian.org\n\nNameSilo, LLC\n\nabuse@namesilo.com\n\nCloudflare, Inc.\n\nabuse@cloudflare.com","Central Iowa Electronic Cigarettes Inc","central-iowa-electronic-cigarettes-inc-614670-05072021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcentral-iowa-electronic-cigarettes-inc-614670-05072021","2026-10-26T08:08:13.052941+00:00","2021-05-18","614670","Corey Halfhill","2026-08-20T03:07:40.407+00:00","2021-05-07",{"id":125,"raw":126,"subject":12,"body_html":130,"body_text":131,"firm_name":132,"letter_id":133,"created_at":134,"fei_number":19,"letter_url":135,"updated_at":136,"action_type":22,"case_status":23,"posted_date":137,"marcs_cms_no":138,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":139,"body_fetched_at":140,"delivery_method":46,"recipient_title":19,"reference_number":19,"action_taken_date":141,"medical_device_id":19,"response_letter_date":19},2633,[127,128,129,11,12,13,13,13],"\u003Ctime datetime=\"2022-06-07T13:20:00Z\">06\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-03T04:00:00Z\">06\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzerocig-dba-aristo-electronic-cigars-634686-06032022\">Zerocig dba Aristo Electronic Cigars\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Moor\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Zerocig dba Aristo Electronic Cigars\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>401 S Lincoln Ave, Ste M\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Corona\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92882-7177\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:zerocigs@gmail.com\"> zerocigs@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:aristocigars@gmail.com\"> aristocigars@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 3, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear David Moor,\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the websites https:\u002F\u002Fwww.zerocig.com and https:\u002F\u002Fwww.aristocigars.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the websites https:\u002F\u002Fwww.zerocig.com and https:\u002F\u002Fwww.aristocigars.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order, for example: ARISTO Reserve E Cigar Juice Carmilla Clouds, ARISTO Reserve E Cigar Juice Cuban Robusto, and ARISTO Reserve E Cigar Juice CUBANO.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201777, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS, USPS, and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Zero Cig\u003Cbr>\n1251 Pomona Rd\u003Cbr>\nCorona, CA 92882-7157\u003C\u002Fp>\n\n\u003Cp>Zerocig.com\u003Cbr>\nP.O. Box 2195\u003Cbr>\nGoodlettsville, TN 37070\u003Cbr>\ninvestorrelations@zerocig.com\u003C\u002Fp>\n\n\u003Cp>Green Foot Media LLC\u003Cbr>\nAtt: David Moor\u003Cbr>\n3791 Middleburg Pl\u003Cbr>\nCorona, CA 92881\u003C\u002Fp>\n\n\u003Cp>Whois Privacy Protection Service, Inc.\u003Cbr>\nwtwrylpgvw@whoisprivacyprotect.com\u003C\u002Fp>\n\n\u003Cp>eNom, LLC\u003Cbr>\nabuse@enom.com\u003C\u002Fp>\n\n\u003Cp>Cloudflare, Inc.\u003Cbr>\nabuse@cloudflare.com\u003C\u002Fp>\n\n\u003Cp>Domain.com, LLC\u003Cbr>\ncompliance@domain-inc.net\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDavid Moor\n\nZerocig dba Aristo Electronic Cigars\n\n401 S Lincoln Ave, Ste M\n\nCorona, CA 92882-7177\n\nUnited States\n\nzerocigs@gmail.com\n\naristocigars@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 3, 2022\n\nWARNING LETTER\n\nDear David Moor,\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the websites https:\u002F\u002Fwww.zerocig.com and https:\u002F\u002Fwww.aristocigars.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the websites https:\u002F\u002Fwww.zerocig.com and https:\u002F\u002Fwww.aristocigars.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order, for example: ARISTO Reserve E Cigar Juice Carmilla Clouds, ARISTO Reserve E Cigar Juice Cuban Robusto, and ARISTO Reserve E Cigar Juice CUBANO.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201777, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS, USPS, and Electronic Mail\n\ncc:\n\nZero Cig\n\n1251 Pomona Rd\n\nCorona, CA 92882-7157\n\nZerocig.com\n\nP.O. Box 2195\n\nGoodlettsville, TN 37070\n\ninvestorrelations@zerocig.com\n\nGreen Foot Media LLC\n\nAtt: David Moor\n\n3791 Middleburg Pl\n\nCorona, CA 92881\n\nWhois Privacy Protection Service, Inc.\n\nwtwrylpgvw@whoisprivacyprotect.com\n\neNom, LLC\n\nabuse@enom.com\n\nCloudflare, Inc.\n\nabuse@cloudflare.com\n\nDomain.com, LLC\n\ncompliance@domain-inc.net","Zerocig dba Aristo Electronic Cigars","zerocig-dba-aristo-electronic-cigars-634686-06032022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzerocig-dba-aristo-electronic-cigars-634686-06032022","2026-10-26T08:10:38.687736+00:00","2022-06-07","634686","David Moor","2026-08-20T01:51:02.953+00:00","2022-06-03",{"id":143,"raw":144,"subject":12,"body_html":148,"body_text":149,"firm_name":150,"letter_id":151,"created_at":134,"fei_number":19,"letter_url":152,"updated_at":153,"action_type":22,"case_status":23,"posted_date":154,"marcs_cms_no":155,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":156,"body_fetched_at":157,"delivery_method":46,"recipient_title":19,"reference_number":19,"action_taken_date":158,"medical_device_id":19,"response_letter_date":19},2851,[145,146,147,11,12,13,13,13],"\u003Ctime datetime=\"2022-02-22T14:20:00Z\">02\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-14T05:00:00Z\">02\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangdong-sigelei-electronic-technology-co-ltd-dba-sigelei-vape-inc-627065-02142022\">Guangdong Sigelei Electronic Technology Co., Ltd. d\u002Fb\u002Fa Sigelei Vape, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ying Liu and Tom Li\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Guangdong Sigelei Electronic Technology Co., Ltd. d\u002Fb\u002Fa Sigelei Vape, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1500 South Milliken Ave, Suite F\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ontario\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91761\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tom@sigelei.com\"> tom@sigelei.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@sigelei.com\"> sales@sigelei.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:daisy@sigelei.com\"> daisy@sigelei.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 14, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ying Liu and Tom Li:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website http:\u002F\u002Fsigelei.com and determined that the ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are components or parts of products made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website http:\u002F\u002Fsigelei.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order including: Sigelei Humvee 80 and Sigelei 213 Fog Coil.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001221 on September 7, 2020. However, FDA issued a negative action for PMTA STN PM0001221 in the form of a Refuse to Accept determination on February 5, 2021 which covers six products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by PMTA STN PM0001221 that resulted in a Refuse to Accept determination, are adulterated and misbranded.\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003Cbr>\n\u003Cbr>\nPlease note your reference number, RW2201741 in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>GuangDong Sigelei Electronic Tech Co., Ltd\u003Cbr>\nfrankyu@sigelei.com\u003Cbr>\nmarketing@sigelei.com\u003C\u002Fp>\n\n\u003Cp>Alibaba Cloud Computing (Beijing) Co., Ltd\u003Cbr>\nDomainAbuse@service.aliyun.com\u003C\u002Fp>\n\n\u003Cp>Alibaba NOC\u003Cbr>\nintlabuse@list.alibaba.com\u003Cbr>\nabuse@alibaba.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nYing Liu and Tom Li\n\nGuangdong Sigelei Electronic Technology Co., Ltd. d\u002Fb\u002Fa Sigelei Vape, Inc.\n\n1500 South Milliken Ave, Suite F\n\nOntario, CA 91761\n\nUnited States\n\ntom@sigelei.com\n\nsales@sigelei.com\n\ndaisy@sigelei.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 14, 2022\n\nWARNING LETTER\n\nDear Ying Liu and Tom Li:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website http:\u002F\u002Fsigelei.com and determined that the ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are components or parts of products made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website http:\u002F\u002Fsigelei.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order including: Sigelei Humvee 80 and Sigelei 213 Fog Coil.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001221 on September 7, 2020. However, FDA issued a negative action for PMTA STN PM0001221 in the form of a Refuse to Accept determination on February 5, 2021 which covers six products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by PMTA STN PM0001221 that resulted in a Refuse to Accept determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201741 in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nGuangDong Sigelei Electronic Tech Co., Ltd\n\nfrankyu@sigelei.com\n\nmarketing@sigelei.com\n\nAlibaba Cloud Computing (Beijing) Co., Ltd\n\nDomainAbuse@service.aliyun.com\n\nAlibaba NOC\n\nintlabuse@list.alibaba.com\n\nabuse@alibaba.com","Guangdong Sigelei Electronic Technology Co., Ltd. d\u002Fb\u002Fa Sigelei Vape, Inc.","guangdong-sigelei-electronic-technology-co-ltd-dba-sigelei-vape-inc-627065-02142022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangdong-sigelei-electronic-technology-co-ltd-dba-sigelei-vape-inc-627065-02142022","2026-10-26T08:08:51.208823+00:00","2022-02-22","627065","Ying Liu and Tom Li","2026-08-20T02:09:37.539+00:00","2022-02-14",8,{"510k":161,"classification":162,"enforcement":163,"event":164,"event_backfill":165,"pma":166,"warning_letter":167},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]